Show simple item record

dc.creatorKochhar, Sonali
dc.creatorKim, Denny
dc.creatorExcler, ean-Louis
dc.creatorCondit, Richard C.
dc.creatorRobertson, James S.
dc.creatorDrew, Stephen
dc.creatorWhelan, Mike
dc.creatorWood, David
dc.creatorFast, Patricia E.
dc.creatorGurwith, Marc
dc.creatorKlug, Bettina
dc.creatorKhuri-Bulos, Najwa
dc.creatorSmith, Emily R.
dc.creatorChen, Robert T
dc.creatorFor the Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
dc.date.accessioned2020-09-16T14:53:36Z
dc.date.available2020-09-16T14:53:36Z
dc.date.created2020-06-15
dc.identifier.issn0264-410Xspa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S0264410X20308306?via%3Dihubspa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/13328
dc.format.extent6 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherVaccinespa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectBrighton Collaborationspa
dc.subjectCEPIspa
dc.subjectVaccinespa
dc.subjectBenefit-riskspa
dc.subjectSafetyspa
dc.subjectProteinspa
dc.subjectRecombinantspa
dc.subjectPeptidespa
dc.subjectTemplatespa
dc.titleThe Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccinesspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAcceso restringidospa
dc.identifier.doihttps://doi.org/10.1016/j.vaccine.2020.06.044spa
dc.description.abstractenglishSeveral protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of protein vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of such a vaccine platform. The structured and standardized assessment provided by the template would also help contribute to improved public acceptance and communication of licensed protein vaccines.spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record